Calliditas Therapeutics Investor Relations Material
Latest events
Q2 2024
Calliditas Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Calliditas Therapeutics
Access all reports
Calliditas Therapeutics AB, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Its lead product candidate is Nefecon that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden.
Key slides for Calliditas Therapeutics
Q2 2024
Calliditas Therapeutics
Q2 2024
Calliditas Therapeutics
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
CALTX
Country
🇸🇪 Sweden